ReviewInternational journal of molecular sciences2020
Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Functions and mechanisms of exosomal lncRNAs in esophageal cancer.Discover oncology · 2026Review
- Bright side of the dark genome: antigens for next-gen cancer vaccines.Journal for immunotherapy of cancer · 2026Review
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- Non-invasive assessment of programmed cell death ligand-1 expression usingScientific reports · 2024Article
- Article
- Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.Cancer immunology research · 2024Article
- Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2023Review
- Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States.Current oncology (Toronto, Ont.) · 2023Observational
- GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers.BMC medical genomics · 2022Article
- Tumor Microenvironment of Esophageal Cancer.Cancers · 2021Review
- Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.Annals of translational medicine · 2021Article
- Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).International journal of molecular medicine · 2021Review
- Inflammation-Induced Tumorigenesis and Metastasis.International journal of molecular sciences · 2021Review
- Article
- A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).Annals of translational medicine · 2021Article
- A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.Journal of thoracic disease · 2020Article
- Circular RNAs With Efficacy in PreclinicalCancer genomics & proteomicsArticle
- MicroRNAs and Corresponding Targets in Esophageal Cancer as ShownCancer genomics & proteomicsReview
- A Retrospective Study of 52 Patients With Primary Small Cell Carcinoma of the Esophagus Treated With Radical Surgery.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignancies, such as non-small cell lung cancer and melanoma. Recent clinical trials also showed promising activity in immune checkpoint inhibitors in pretreated advanced esophageal carcinoma and a potentially significant impact on the outcome of selected patients, independently of histology. Combination studies evaluating immunotherapy and chemotherapy and, in localized disease, radiotherapy are in progress and will hopefully confirm their promises in the near future. However, reliable predictive biomarkers are still lacking. Indeed, at present, the role of programmed cell death ligand 1 expression and other factors (such as microsatellite instability and tumor mutational burden) as predictive biomarkers of benefit to immune checkpoint inhibitors is still controversial. Our aim was to explore the rationale of ICIs in esophageal cancer, review the results already available in multiple settings, and investigate future perspectives with single-agent and combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.